Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NRX Pharmaceuticals, Inc.NRXP · Entity 6523 | CHIEF FINANCIAL OFFICER | December 16, 2022 | December 19, 2022 |
| PDS Biotechnology CorpPDSB · Entity 7939 | Chief Financial Officer | June 15, 2021 | June 17, 2021 |
| RESEARCH FRONTIERS INCREFR · Entity 7794 | CFO & VP-Business Development | February 21, 2020 | February 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NRX Pharmaceuticals, Inc.
Report date December 16, 2022 · Filed December 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 46,337 |
Reported balance
After 2022-12-16 transaction · row 1
1 source rowRow 1 · 2022-12-16 · Purchase · Acquired 30,000 · Balance 46,337 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.11. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.11. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
PDS Biotechnology Corp
Report date June 15, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,647 |
Reported balance
After 2021-06-15 transaction · row 1
1 source rowRow 1 · 2021-06-15 · Purchase · Acquired 17,647 · Balance 17,647 F1: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021.
RESEARCH FRONTIERS INC
Report date February 21, 2020 · Filed February 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 230,454 |
Ending reported balance
After 2020-02-21 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2020-02-21 · Tax withholding · Acquired 13,717 · Balance 152,617 Row 2 · 2020-02-21 · Tax withholding · Acquired 22,158 · Balance 174,775 Row 3 · 2020-02-21 · Tax withholding · Acquired 45,272 · Balance 220,047 Row 4 · 2020-02-21 · Tax withholding · Acquired 5,746 · Balance 225,793 Row 5 · 2020-02-21 · Tax withholding · Acquired 4,661 · Balance 230,454 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.83 · Expires 2026-12-30 | Direct | 280,191 |
Reported balance
After 2020-02-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-21 · Exercise / conversion · Disposed 25,000 · Balance 280,191 F1: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2027-12-30 | Direct | 250,191 |
Reported balance
After 2020-02-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-21 · Exercise / conversion · Disposed 30,000 · Balance 250,191 F1: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2028-04-18 | Direct | 190,100 |
Reported balance
After 2020-02-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-21 · Exercise / conversion · Disposed 60,091 · Balance 190,100 F1: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2029-06-12 | Direct | 170,100 |
Reported balance
After 2020-02-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-21 · Exercise / conversion · Disposed 20,000 · Balance 170,100 F1: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.11 · Expires 2029-12-31 | Direct | 150,100 |
Reported balance
After 2020-02-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-02-21 · Exercise / conversion · Disposed 20,000 · Balance 150,100 F1: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2022 Filed Dec 19, 2022 07:09 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 30,000 | $1.10 | $33,000.00 |
DisclosureSEC source: 0001415889-22-012652 · form4-12192022_121236.xml · nonDerivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,337 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.11. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 07:42 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 7,021 | $1.11 | $7,793.31 |
DisclosureSEC source: 0001415889-22-011778 · form4-11282022_121119.xml · nonDerivative · entry 3 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · Shares purchased though 401(k) plan Disclosed balance after: 16,377 Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 07:42 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 600 | $1.10 | $660.00 |
DisclosureSEC source: 0001415889-22-011778 · form4-11282022_121119.xml · nonDerivative · entry 2 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · Shares purchased though 401(k) plan Disclosed balance after: 9,316 Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 07:42 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 8,716 | $1.12 | $9,761.92 |
DisclosureSEC source: 0001415889-22-011778 · form4-11282022_121119.xml · nonDerivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · Shares purchased though 401(k) plan Disclosed balance after: 8,716 Read SEC document |
| November 25, 2022 Filed Dec 19, 2022 07:08 UTC Amendment | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 7,021 | $1.11 | $7,793.31 |
DisclosureSEC source: 0001415889-22-012650 · form4a-12192022_121206.xml · nonDerivative · entry 3 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,337 F3 · balance_after: Total number of shares held is reduced by 40 shares to correct an arithmetic error in the original Form 4. F4 · ownership.direct: The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error. Read SEC document |
| November 25, 2022 Filed Dec 19, 2022 07:08 UTC Amendment | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 600 | $1.10 | $660.00 |
DisclosureSEC source: 0001415889-22-012650 · form4a-12192022_121206.xml · nonDerivative · entry 2 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,316 F2 · ownership.direct: The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error. Read SEC document |
| November 25, 2022 Filed Dec 19, 2022 07:08 UTC Amendment | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 8,716 | $1.12 | $9,761.92 |
DisclosureSEC source: 0001415889-22-012650 · form4a-12192022_121206.xml · nonDerivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,716 F1 · ownership.direct: The form of ownership has been changed from Indirect to Direct. The original Form 4 stated that these shares were purchased though a 401(k) plan. This Form 4/A is being filed to correct this error. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 22:52 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 17,647 | $8.50 | $149,999.50 |
DisclosureSEC source: 0001140361-21-021491 · form4.xml · nonDerivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,647 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:06 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 202,800 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001140361-21-000334 · form4.xml · derivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,800 Underlying: Common Stock · 202,800 shares Expires 2031-01-04 F1 · derivative.exercise_date: The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 1, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · derivative · entry 10 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,100 Underlying: Common Stock · 20,000 shares Expires 2029-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · derivative · entry 9 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,100 Underlying: Common Stock · 20,000 shares Expires 2029-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Exercise / conversionStock Option (right to buy) · Derivative | 60,091 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · derivative · entry 8 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,100 Underlying: Common Stock · 60,091 shares Expires 2028-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · derivative · entry 7 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,191 Underlying: Common Stock · 30,000 shares Expires 2027-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · derivative · entry 6 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,191 Underlying: Common Stock · 25,000 shares Expires 2026-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents payment of $257,641 aggregate exercise price of these options by the reduction of securities issued by 63,537 shares, resulting in a net issuance of 91,554 shares. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Tax withholdingCommon Stock | 4,661 | $3.11 | $14,495.71 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · nonDerivative · entry 5 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,454 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Tax withholdingCommon Stock | 5,746 | $2.89 | $16,605.94 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · nonDerivative · entry 4 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,793 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Tax withholdingCommon Stock | 45,272 | $1.00 | $45,272.00 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · nonDerivative · entry 3 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,047 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Tax withholdingCommon Stock | 22,158 | $1.06 | $23,487.48 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · nonDerivative · entry 2 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,775 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | Tax withholdingCommon Stock | 13,717 | $1.83 | $25,102.11 |
DisclosureSEC source: 0001493152-20-002886 · ownership.xml · nonDerivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,617 Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:00 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | GrantStock Option(right to buy) · Derivative | 20,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001493152-20-000036 · form4.xml · derivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,191 Underlying: Common Stock · 20,000 shares Expires 2029-12-30 Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 13:00 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | GrantStock Option(right to buy) · Derivative | 20,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001493152-19-009286 · form4.xml · derivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,191 Underlying: Common Stock · 20,000 shares Expires 2029-06-12 Read SEC document |
| May 03, 2018 Filed May 4, 2018 20:05 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | GrantStock Option(right to buy) · Derivative | 60,091 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001493152-18-006262 · form4.xml · derivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,191 Underlying: Common Stock · 60,091 shares Expires 2028-04-18 Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | GrantStock Option(right to buy) · Derivative | 30,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001493152-18-000098 · form4.xml · derivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,100 Underlying: Common Stock · 30,000 shares Expires 2027-12-30 Read SEC document |
| September 12, 2017 Filed Sep 13, 2017 12:30 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | PurchaseCommon Stock | 4,000 | $1.15 | $4,600.00 |
DisclosureSEC source: 0001493152-17-010518 · form4.xml · nonDerivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Buisness Develpoment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,900 Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 21:25 UTC | RESEARCH FRONTIERS INC REFR · Entity 7794 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001493152-17-000050 · form4.xml · derivative · entry 1 VAN VOORHEES SETH · CIK 0001284934 · CFO & VP-Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,100 Underlying: Common Stock · 25,000 shares Expires 2026-12-30 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.